• myGriffith
    • Staff portal
    • Contact Us⌄
      • Future student enquiries 1800 677 728
      • Current student enquiries 1800 154 055
      • International enquiries +61 7 3735 6425
      • General enquiries 07 3735 7111
      • Online enquiries
      • Staff phonebook
    View Item 
    •   Home
    • Griffith Research Online
    • Conference outputs
    • View Item
    • Home
    • Griffith Research Online
    • Conference outputs
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

  • All of Griffith Research Online
    • Communities & Collections
    • Authors
    • By Issue Date
    • Titles
  • This Collection
    • Authors
    • By Issue Date
    • Titles
  • Statistics

  • Most Popular Items
  • Statistics by Country
  • Most Popular Authors
  • Support

  • Contact us
  • FAQs
  • Admin login

  • Login
  • Rate of patients receiving second-line treatment for metastatic colorectal cancer in a real-world setting

    Author(s)
    Ups, Katherine
    Francesconi, Alessandra
    Ryan, Elizabeth G
    Griffith University Author(s)
    Francesconi, Alessandra
    Year published
    2021
    Metadata
    Show full item record
    Abstract
    Background: Colorectal cancer is the third most common cancer diagnosed in Australia. Although a large portion (46.4%) present at an early stage, up to 45% relapse and many others present with de novo metastatic disease.1, 2 Although the treatment landscape for metastatic colorectal cancer (mCRC) is rapidly evolving, little is known about real-world impact of various regimens or utilisation rates of treatments beyond first-line. Aims: To evaluate the real-world rates of mCRC patients receiving systemic therapy beyond first line at a regional cancer centre (Sunshine Coast Hospital and Health Service - SCHHS). As well as the ...
    View more >
    Background: Colorectal cancer is the third most common cancer diagnosed in Australia. Although a large portion (46.4%) present at an early stage, up to 45% relapse and many others present with de novo metastatic disease.1, 2 Although the treatment landscape for metastatic colorectal cancer (mCRC) is rapidly evolving, little is known about real-world impact of various regimens or utilisation rates of treatments beyond first-line. Aims: To evaluate the real-world rates of mCRC patients receiving systemic therapy beyond first line at a regional cancer centre (Sunshine Coast Hospital and Health Service - SCHHS). As well as the regimen choice and relative rates of treatment progression of the different regimens utilised in the first line. Methods: A retrospective analysis of all patients with mCRC who received first-line palliative systemic chemotherapy between January 2014 and December 2020 at SCHHS has been conducted. Real-world treatment patterns including rates of progression and survival were also examined. Results: During this time period, 249 patients diagnosed with mCRC received first-line treatment at our centre. Of these patients, 136 (54.6%) patients progressed to second-line treatment. Progression rates dropped through treatment lines, with 18.9% and 5.2% of patients receiving 3rdand 4thline treatments respectively. Doublet therapy with or without a biological agent was the most commonly used first-line treatment option with 199 patients (79.9%). Conclusion: Overall 54.6% of mCRC patients at our centre progressed onto second-line treatment therapy, which is higher than the current literature with studies reporting rates of 48.9% and 52.2%.3, 4 These results show that at our centre, although percentages are lower than initially perceived, they are higher than other international statistics. Welfare AIoHa. Cancer in Australia 2019. Canberra: AIHW; 2019. Wilhelmsen M, Kring T, Jorgensen LN, Madsen MR, Jess P, Bulut O, et al. Determinants of recurrence after intended curative resection for colorectal cancer. Scand J Gastroenterol. 2014;49(12):1399-408. Hess LM, Cui ZL, Mytelka DS, Han Y, Goodloe R, Schelman W. Treatment patterns and survival outcomes for patients receiving second-line treatment for metastatic colorectal cancer in the USA. Int J Colorectal Dis. 2019;34(4):581-8. Jeremy Snider EWSAJSGSWCRFVS, Scott David R. Metastatic colorectal cancer (mCRC) treatment patterns in the Medicare population. Journal of Clinical Oncology. 2018;36(4):823.
    View less >
    Conference Title
    Asia-Pacific journal of clinical oncology
    Volume
    17
    Issue
    59
    DOI
    https://doi.org/10.1111/ajco.13716
    Subject
    Oncology and carcinogenesis
    Science & Technology
    Life Sciences & Biomedicine
    Oncology
    Publication URI
    http://hdl.handle.net/10072/412050
    Collection
    • Conference outputs

    Footer

    Disclaimer

    • Privacy policy
    • Copyright matters
    • CRICOS Provider - 00233E
    • TEQSA: PRV12076

    Tagline

    • Gold Coast
    • Logan
    • Brisbane - Queensland, Australia
    First Peoples of Australia
    • Aboriginal
    • Torres Strait Islander